Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1191/0269216306pm1118cr | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zuclopenthixol dihydrochloride for schizophrenia.
Cochrane Database Syst Rev
November 2017
Sheffield Health and Social Care, NHS Foundation Trust, Fulwood House, Old Fulwood Road, Sheffield, UK, S10 3TH.
Background: Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses.
Objectives: To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia.
Manganese toxicity in critical care: Case report, literature review and recommendations for practice.
J Intensive Care Soc
August 2016
Department of Nutrition and Dietetics, Royal Surrey County Hospital, Surrey, UK.
We present the case of a 62-year-old man on the intensive care unit with pancreatitis. Since early in his admission, and for the remainder of his prolonged stay in intensive care, he has received parenteral nutrition for intestinal failure. The whole blood manganese concentration was significantly increased after 2½ months of parenteral nutrition (PN).
View Article and Find Full Text PDFAsenapine for bipolar disorder.
Neuropsychiatr Dis Treat
December 2015
University Hospitals Case Medical Center, Cleveland, OH, USA ; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Asenapine (Saphris(®)) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the treatment of schizophrenia in adults, as well as the treatment of acute manic or mixed episodes of bipolar I in both adult and pediatric populations. Asenapine is a tetracyclic drug with antidopaminergic and antiserotonergic activity with a unique sublingual route of administration. In this review, we examine and summarize the available literature on the safety, efficacy, and tolerability of asenapine in the treatment of bipolar disorder (BD).
View Article and Find Full Text PDFUnusual features of Creutzfeldt-Jakob disease followed-up in a memory clinic.
J Neurol
April 2014
Centre Mémoire de Ressources et de Recherches, Centre National de référence, Université de Lille-Nord de France, Maladie d'Alzheimer du sujet jeune, Labex DISTALZ, CHU, 59000, Lille, France,
Sporadic Creutzfeldt-Jakob disease (sCJD) generally manifests itself by cognitive or rapidly progressive motor symptoms. An atypical onset or an unusual evolution may delay the diagnosis. Among patients with a confirmed diagnosis of sCJD following a post-mortem neuropathological examination at the Neuropathology Centre of Lille, France, those who had presented with atypical cognitive disorders at onset were included in the study.
View Article and Find Full Text PDFEvidence-based medicine (EBM) is a broad concept, but the key elements include the incorporation of clinical judgment (which requires clinical experience) together with relevant scientific evidence while remaining mindful of the individual patient's values and preferences. Using the framework and philosophy of EBM, this systematic review summarizes the pharmacology, efficacy, and tolerability of newly approved oral antipsychotics, including iloperidone, asenapine, and lurasidone, and outlines what is known about agents that are in late-stage clinical development, such as cariprazine, brexpiprazole, zicronapine, bitopertin, and EVP-6124. Potential advantages and disadvantages of these agents over existing antipsychotics are outlined, centered on clinically relevant issues such as the potential for weight gain and metabolic abnormalities, potential association with somnolence/sedation, extra-pyramidal side effects, akathisia, and prolongation of the electrocardiogram (ECG) QT interval, as well as practical issues regarding dosing instructions, titration requirements, and drug-drug interactions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!